Tumor growth was assessed in xenograft models.<h4>Results</h4>GLIS3 was consistently upregulated in STAD across public datasets and in the clinical cohort (median H-score: 112 vs 39, <i>P</i> < 0.001) and was associated with adverse clinicopathological features and poor survival. The gene discussed is GLIS3; the disease is neoplasm.